聚桂醇硬化剂治疗婴幼儿皮肤血管瘤的临床疗效  

Therapic effect of lauromacrogol sclerotherapy on infantile hemangioma

作　　者：江珊[1] 陆玲[1] 胡英姿[1] 李慧[1] 梁虹[1] 

机构地区：[1]武汉大学人民医院皮肤科,430060

出　　处：《中华医学美学美容杂志》2013年第5期359-361,共3页Chinese Journal of Medical Aesthetics and Cosmetology

摘　　要：目的 临床观察聚桂醇注射液局部瘤体内注射治疗婴幼儿皮肤血管瘤的疗效.方法 对30例血管瘤患儿局部瘤体内注射硬化剂——聚桂醇注射液,定期观察和记录血管瘤大小、质地、颜色的变化,并随时处理治疗过程中出现的不良反应.根据瘤体消退情况确定治疗次数.治疗结束后6个月,按4级评分法对疗效进行评价.结果 30例患儿均完成治疗全程,其中达到I级疗效者2例（6.7％）,Ⅱ级疗效者4例（13.3％）,Ⅲ级疗效者5例（16.7％）,Ⅳ级疗效者19例（63.3％）.瘤体直径越小,硬化剂注射治疗的次数越少,且治疗效果越好.早期积极给予聚桂醇硬化剂治疗的效果较好.所有患儿随访6个月均未复发,也未出现严重的不良反应.结论 聚桂醇硬化疗法是一种安全、有效地治疗婴幼儿血管瘤的方法.Objective To investigate the effect of intralesional lauromacrogol therapy on infantile hemangioma.Methods 30 cases all received intralesional injection of lauromacrogol.The changes of tumor size,texture and color were monitored and recorded.The adverse effects after medication were observed and managed accordingly.The adverse effects after medication were observed.The times of treatment were determined according to degree of reduction of tumor volume.To assess the efficacy,a 4 scales system was adopted.Results All patients had completed the treatment and followup.The overall response was scale Ⅰ in 2 cases （6.7 %）,scale Ⅱ efficacy in 4 patients （13.3 %）,scale Ⅲ efficacy in 5 cases （16.7 %） and scale Ⅳ in 19 cases （63.3 %）.The smaller the tumor,the fewer the times of treatment,and the better the results.The effects of treatment were better if patient could be treated by intralesional lauromacrogol therapy in early stage.No severe adverse effects were observed during 6 months of follow-up.Conclusions Intralesional injection of lauromacrogol sclerotherapy is a safe and effective way to treat infantile hemangioma.

关 键 词：血管瘤 硬化疗法 聚桂醇 

分 类 号：R739.5[医药卫生—肿瘤]